FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564677788> ?p ?o ?g. }

• W2564677788 abstract "Abstract Background: Fatigue is common and very distressing among patients with myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH), frequently affecting their quality of life. Often, this is combined with other symptoms such as pain, depression, anxiety, and stress. Limited data exists on the perceived level and impact of fatigue, quality of life and related symptoms in these patients. The objectives are to describe fatigue, quality of life (QOL) and related symptoms in patients with MDS, AA, and PNH by prospectively assessing these using the Functional Assessment of Cancer Therapy-Anemia (FACT-An) for fatigue and QOL (subscales within FACT- An), pain using the Brief Pain Inventory (BPI), and depression, anxiety and stress using the DASS-21, and to define management strategies routinely used. Methods: Surveys were administered via the AA and MDS International Foundation's patient database from 10/2014 through 1/2015 via a secure internet portal associated with the Foundation's website. Descriptive statistics were utilized. Results: Of 313 pts, 145 (46%) had MDS, 84 (27%) had AA, 74 (24%) PNH, and 10 (3%) unreported [31 (10%), >1 diagnosis]. The mean age was 57 years with 210 (67%) female, 197 (92%) white among 214 with known race and 70 (25%) received a blood transfusion in the past 90 days. The mean fatigue score overall was 25 (range 1-52) and 28, 25, and 24 for AA, MDS, and PNH, respectively, p=0.12. (severe level). The overall quality of life score was 68 (range 10-104) and 67, 69, 67 for AA, MDS, PNH, respectively, p=0.82. Please note with the FACT-An, FACT-G and FACT-F -The higher the score, the better the QOL. The overall ranges for stress were normal; pain and depression, mild; and anxiety, moderate. Among the subgroups, stress was normal (all); pain and depression were mild (all); anxiety was mild in MDS, moderate in AA, PNH. None of the subgroups had statistical significance for these symptoms including anxiety. Most common management strategies used for fatigue in the past month were preserving energy 252 (81%); physical activity 234 (75%); naps 228 (73%). The strategies that were helpful to extremely helpful were preserving energy 216/252 (86%), physical activity 162/234 (69%), and naps 154/228 (68%). Among subgroups, physical activity (p=0.03) and meditation (p=0.03) showed significant differences. Frequency of use 3 or more times/week were preserving energy 166/237 (70%), physical activity 128/226 (57%), and naps 131/213 (62%) among those who indicated the frequency of use. Among subgroups, the frequency of physical activity p= 0.03, eating healthy p=0.005, and counseling p=.005 showed significant differences. Conclusions: There are few patient reported outcomes of fatigue, QOL and related symptoms in this population of rare disorders. Fatigue and QOL are significant challenges with similar findings of fatigue, QOL and related symptoms among the subgroups. However, there were differences among the types of management strategies and the frequency of use among the subgroups. Further focus on development of interventions tailored for AA, MDS, and PNH may assist in better management of fatigue with potential improvement in QOL. Disclosures No relevant conflicts of interest to declare." @default.
• W2564677788 created "2017-01-06" @default.
• W2564677788 creator A5007992301 @default.
• W2564677788 creator A5021499258 @default.
• W2564677788 creator A5028060769 @default.
• W2564677788 creator A5037880857 @default.
• W2564677788 creator A5049475717 @default.
• W2564677788 creator A5061026876 @default.
• W2564677788 creator A5062489393 @default.
• W2564677788 creator A5081888096 @default.
• W2564677788 date "2015-12-03" @default.
• W2564677788 modified "2023-10-15" @default.
• W2564677788 title "Fatigue, Quality of Life and Related Symptoms: Patient Reported Outcomes in Myelodysplastic Syndrome, Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria" @default.
• W2564677788 doi "https://doi.org/10.1182/blood.v126.23.4456.4456" @default.
• W2564677788 hasPublicationYear "2015" @default.
• W2564677788 type Work @default.
• W2564677788 sameAs 2564677788 @default.
• W2564677788 citedByCount "0" @default.
• W2564677788 crossrefType "journal-article" @default.
• W2564677788 hasAuthorship W2564677788A5007992301 @default.
• W2564677788 hasAuthorship W2564677788A5021499258 @default.
• W2564677788 hasAuthorship W2564677788A5028060769 @default.
• W2564677788 hasAuthorship W2564677788A5037880857 @default.
• W2564677788 hasAuthorship W2564677788A5049475717 @default.
• W2564677788 hasAuthorship W2564677788A5061026876 @default.
• W2564677788 hasAuthorship W2564677788A5062489393 @default.
• W2564677788 hasAuthorship W2564677788A5081888096 @default.
• W2564677788 hasConcept C118552586 @default.
• W2564677788 hasConcept C126322002 @default.
• W2564677788 hasConcept C139719470 @default.
• W2564677788 hasConcept C159110408 @default.
• W2564677788 hasConcept C162324750 @default.
• W2564677788 hasConcept C1862650 @default.
• W2564677788 hasConcept C187212893 @default.
• W2564677788 hasConcept C2776867660 @default.
• W2564677788 hasConcept C2777346216 @default.
• W2564677788 hasConcept C2778248108 @default.
• W2564677788 hasConcept C2779951463 @default.
• W2564677788 hasConcept C2780007613 @default.
• W2564677788 hasConcept C2780817109 @default.
• W2564677788 hasConcept C2781440808 @default.
• W2564677788 hasConcept C558461103 @default.
• W2564677788 hasConcept C71924100 @default.
• W2564677788 hasConceptScore W2564677788C118552586 @default.
• W2564677788 hasConceptScore W2564677788C126322002 @default.
• W2564677788 hasConceptScore W2564677788C139719470 @default.
• W2564677788 hasConceptScore W2564677788C159110408 @default.
• W2564677788 hasConceptScore W2564677788C162324750 @default.
• W2564677788 hasConceptScore W2564677788C1862650 @default.
• W2564677788 hasConceptScore W2564677788C187212893 @default.
• W2564677788 hasConceptScore W2564677788C2776867660 @default.
• W2564677788 hasConceptScore W2564677788C2777346216 @default.
• W2564677788 hasConceptScore W2564677788C2778248108 @default.
• W2564677788 hasConceptScore W2564677788C2779951463 @default.
• W2564677788 hasConceptScore W2564677788C2780007613 @default.
• W2564677788 hasConceptScore W2564677788C2780817109 @default.
• W2564677788 hasConceptScore W2564677788C2781440808 @default.
• W2564677788 hasConceptScore W2564677788C558461103 @default.
• W2564677788 hasConceptScore W2564677788C71924100 @default.
• W2564677788 hasLocation W25646777881 @default.
• W2564677788 hasOpenAccess W2564677788 @default.
• W2564677788 hasPrimaryLocation W25646777881 @default.
• W2564677788 hasRelatedWork W1973003045 @default.
• W2564677788 hasRelatedWork W2066562022 @default.
• W2564677788 hasRelatedWork W2143632050 @default.
• W2564677788 hasRelatedWork W2370740663 @default.
• W2564677788 hasRelatedWork W2388345616 @default.
• W2564677788 hasRelatedWork W2404782904 @default.
• W2564677788 hasRelatedWork W2519368911 @default.
• W2564677788 hasRelatedWork W2531387757 @default.
• W2564677788 hasRelatedWork W2562866800 @default.
• W2564677788 hasRelatedWork W2572927045 @default.
• W2564677788 hasRelatedWork W2589746596 @default.
• W2564677788 hasRelatedWork W2774759291 @default.
• W2564677788 hasRelatedWork W2793680327 @default.
• W2564677788 hasRelatedWork W2807757698 @default.
• W2564677788 hasRelatedWork W2991387429 @default.
• W2564677788 hasRelatedWork W3011820589 @default.
• W2564677788 hasRelatedWork W3013618817 @default.
• W2564677788 hasRelatedWork W3025584464 @default.
• W2564677788 hasRelatedWork W3108718536 @default.
• W2564677788 hasRelatedWork W3183712164 @default.
• W2564677788 isParatext "false" @default.
• W2564677788 isRetracted "false" @default.
• W2564677788 magId "2564677788" @default.
• W2564677788 workType "article" @default.